{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:46:51Z","timestamp":1786715211458,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Adv Pharm Technol Res"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/2231-4040.197384","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T04:00:16Z","timestamp":1485316816000},"page":"25","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of glaucoma management with monotherapy medications in Egypt"],"prefix":"10.4103","volume":"8","author":[{"given":"AmalAbd-Elaal","family":"El-Khamery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AmirIbrahim","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HassanEisa Hassan","family":"Swify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AlaaIbrahim","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2231-4040.197384-1","first-page":"468","volume-title":"Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: An overview of reviews","author":"Daka","year":"2014","journal-title":"Croat Med J"},{"key":"key-10.4103\/2231-4040.197384-2","first-page":"3518","volume-title":"Glaucoma","author":"King","year":"2013","journal-title":"BMJ"},{"key":"key-10.4103\/2231-4040.197384-3","first-page":"247","volume-title":"Antiglaucoma pharmacotherapy","author":"Tataru","year":"2012","journal-title":"J Med Life"},{"key":"key-10.4103\/2231-4040.197384-4","first-page":"513","volume-title":"The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension","author":"van","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"key-10.4103\/2231-4040.197384-5","first-page":"460483","volume-title":"The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: A prospective study","author":"Aydin","year":"2014","journal-title":"J Ophthalmol"},{"key":"key-10.4103\/2231-4040.197384-6","first-page":"120","volume-title":"Mode of action, clinical profile and significance of beta-blockers in antiglaucoma therapy","author":"Schlote","year":"2013","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.4103\/2231-4040.197384-7","first-page":"127","volume-title":"Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy","author":"Yu","year":"2013","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.4103\/2231-4040.197384-8","first-page":"618","volume-title":"Pharmacoeconomics of new medications for common chronic ophthalmic diseases","author":"Hirsch","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"key-10.4103\/2231-4040.197384-9","first-page":"21","volume-title":"Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China","author":"Wang","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"key-10.4103\/2231-4040.197384-10","first-page":"365","volume-title":"Cost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma","author":"Berenson","year":"2011","journal-title":"Am J Manag Care"},{"key":"key-10.4103\/2231-4040.197384-11","first-page":"16","volume-title":"Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension","author":"Frenkel","year":"2007","journal-title":"BMC Ophthalmol"},{"key":"key-10.4103\/2231-4040.197384-12","volume-title":"The efficacy and safety of brimonidine 0.2% compared with timolol 0","author":"Chen","year":"5% i","journal-title":""},{"key":"key-10.4103\/2231-4040.197384-13","first-page":"955","volume-title":"Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension - Comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine\/prostaglandins therapy versus combination placebo\/prostaglandins therapy","author":"Araie","year":"2012","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"key-10.4103\/2231-4040.197384-14","first-page":"106","volume-title":"Cost analysis of glaucoma medications","author":"Rylander","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/2231-4040.197384-15","first-page":"20","volume-title":"The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma","author":"van","year":"2012","journal-title":"Acta Ophthalmol"}],"container-title":["Journal of Advanced Pharmaceutical Technology & Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:26:15Z","timestamp":1786713975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2231-4040.197384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"alternative-id":["197384"],"URL":"https:\/\/doi.org\/10.4103\/2231-4040.197384","relation":{},"ISSN":["2231-4040"],"issn-type":[{"value":"2231-4040","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}